Pre-earnings options volume in Protagonist Therapeutics is 2.0x normal with calls leading puts 8:3. Implied volatility suggests the market is anticipating a move near 7.3%, or $1.74, after results are released. Median move over the past eight quarters is 1.9%.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PTGX:
- Protagonist Therapeutics Surges 52% after Successful Phase 2 Trial
- Protagonist Therapeutics reports ‘positive’ results from FRONTIER 1 Phase 2b
- Protagonist Therapeutics participates in a conf call hosted by Piper Sandler
- J&J conference call comments ‘a good sign’ for Protagonist, says JMP Securities
- Piper Sandler ‘excited’ about Protagonist ahead of PN-235 data
